Increased risk of graft-versus-host-disease (GVHD) has been described in hematopoietic stem cell transplantation recipients when the donor is a parous woman. Cells from prior pregnancies are now known to persist in women and could contribute to GVHD. We 
Introduction
Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT) and a leading cause of mortality and morbidity. HLA incompatibility is the strongest risk factor for GVHD, but other factors including donor parity are thought to play a role. [1] [2] [3] [4] The reason(s) for increased risk of GVHD when the donor is a parous woman is unknown. Flowers et al suggested that allosensitization of maternal T-cells to fetal minor histocompatibility antigens during pregnancy could prime cells to similar antigens in a transplant recipient. 1 However, the discovery that fetal cells persist in the circulation of parous women decades after childbirth raises the question whether non-HLA-matched fetal cells are present in apheresis products and could contribute to GVHD. Fetal microchimerism (FMc) refers to low levels of fetal cells harbored by the mother, which persist at least 38 years postpartum. 5, 6 FMc has also been described in cellular subsets including CD34 + CD38 + , CD3 (including CD4 and CD8), CD19, CD14, and CD56/16 subsets. 6, 7 Our objective was to determine whether male DNA (probable FMc) is present in apheresis products from female donors. Growth factor mobilized peripheral blood mononuclear cells (G-PBMC) and CD34-enriched apheresis products of female donors were tested using real-time quantitative PCR (QPCR) for DYS14, a Y-chromosome specific sequence.
Methods:
Study design and subjects. For these subjects, pregnancy and transfusion history was known. Quantitation of male DNA by real-time QPCR. Genomic DNA was extracted using Promega Wizard Purification Kits (Promega, Madison, WI) according to manufacturer's instructions. QPCR methods and -globin primers have previously been described. 8, 9 We previously reported QPCR using DYS14 as a Y-chromosome specific target. 10 Twelve aliquots of DNA were tested from each donor. Two additional DNA aliquots were The x-axis represents the number of cycles of a PCR reaction and the y-axis is fluorescence intensity over background. With increasing cycle number, smaller DNA quantities amplify. Each sample is tested for -globin (measure of total DNA) and DYS14 (measure of male DNA) with quantitative results assessed by the intersection of the amplification plots with the threshold.
Peripheral blood mononuclear cell mobilization (PBMC) and

Results and Discussion:
Overall, we found male DNA in 34% of G-PBMC samples and 48% of CD34-selected samples. The mean number of gEq assayed per patient was 121,717 (range Each symbol represents results for one of a total of 50 apheresis products tested, deriving from 46 women. Four women with SSc had both G-PBMC and CD34-enriched products tested (all samples negative.)
We present data that male DNA (probable FMc) is not uncommon in G-PBMC and CD34-enriched apheresis products from female donors. The male DNA most likely resulted from a prior pregnancy, although in some subjects it could derive from a blood transfusion as we lacked this history in unidentified subjects. However, the highest level of male DNA was presumably of fetal origin, as the woman had no blood transfusions and had given birth to 3 sons. Thus, our results suggest donor FMc is present both in G-PBMC and CD34-enriched apheresis products, although the FMc in these products could derive from a variety of cell lineages. Estimating from the lowest quantity of male DNA detected (1 gEq/mil), this would represent approximately 10,000 -40,000 male cells infused during a typical HSCT using G-PBMC. In addition to FMc, other sources of chimerism may be transferred during HSCT.
Non-irradiated blood transfusions can result in persistent microchimerism or lead to transfusion-associated GVHD. 13, 14 Cells from the mother traffic into the fetus during pregnancy and persist into adult life. 15 Chimerism may also develop with cell transfer between twins in utero. 5 These sources of chimerism could contribute to GVHD with male or nulligravid female donors. To our knowledge, no prior studies have addressed the hypothesis that donor FMc is transferred during HSCT or may be implicated in GVHD. The impact of transplanting a small population of non-HLA-matched cells on the development of GVHD is unknown and merits further study.
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